Professor Middleton holds the chair of Neuroepidemiology and Ageing Research at the School of Public Health. He is, also, Honorary Consultant with the Imperial College Healthcare NHS Trust Hospitals. He trained in Medicine and completed his Neurology training at the Louis Pasteur University Hospital in Strasbourg and obtained a Medical Doctorate Degree and, also, the French National Board in Neurology. He was then appointed Clinical Fellow of the Presbyterian Hospital and Visiting Assistant Professor of Columbia University in New York. His initial research was in clinical electrophysiology and neurogenetics of inherited neuromuscular diseases, mainly in the identification and mapping of the Vitamin E Deficiency Ataxia (AVED), rare forms of Hereditary Motor Neuropathy and a Congenital Myasthenia Syndrome due to mutations in acetylcholine receptor ε-subunit gene. Professor Middleton was awarded, in 1990, a US- AID centre grant to create the Cyprus Institute of Neurology and Genetics (CING), of which he became first Chairman (1990-1999).
In 1999, he joined the GlaxoWellcome Genetics Research Directorate and then led the development of the GSK Translational Medicine and Genetics (TMG), based in London. TMG was a new R&D function that combined medical genetics, imaging, biomarkers and experimental medicine. In this role, he led the development of the Clinical Imaging Centre at the Hammersmith Hospital (now known as Imanova), the Experimental Medicine Unit at Addenbrooke’s Hospital (Cambridge) and biomarker laboratories in the US. His research organization also included medical genetics groups in the UK, US, Italy and Japan. He served on the Medical Research Council in years 2005-2008 and as non-executive director of the West London NHS Mental Health Trust (2011-2015). Following the Global Dementia G7 Summits in London (December 2013 and June 2014), he was appointed as clinical lead and chair of the Clinical & Technology Expert Group (CTEG) until May 2015. During the year 2015, he also served on the interim Management Board of the European EIT-Health.
He joined Imperial College London (ICL) in 2007 as Professor of Neurology, Head of the Division of Neuroscience and Mental Health (2007-2010) and Honorary Consultant Neurologist of the Imperial College Healthcare NHS Trust. He is, currently, the principal investigator of the Chariot register [a cohort of > 28,000 healthy volunteers for Alzheimer’s disease (AD) prevention studies, in West London], the industry sponsored Chariot PRO biomarker- enriched observational study on the natural history of the early stages of AD and the Funnel study for early AD. He is the Chief UK Investigator for two dementia clinical trials and the principal investigator of a study of gene-environment interactions in Parkinson’s disease and related dementias and was the principal investigator of the Parkinson’s UK Brain Bank, held at Imperial College London, during the years 2009-2014. He served as the clinical lead for the Department of Health Global Dementia Initiative, formed post the Global Dementia Summit, hosted by the British Prime Minister in December 2013. He has authored / co-authored 151 publications. He is the Principal Investigator of the European programme “Caring for the Ageing Re-imagined in Europe” (CARE), which is part of the EIT-Health Educational Campus.
et al., 2015, Cortical Lewy bodies and Aβ burden are associated with prevalence and timing of dementia in Lewy body diseases., Neuropathology and Applied Neurobiology, Vol:42, ISSN:1365-2990, Pages:436-450
et al., 2013, Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs, Nature Genetics, Vol:45, ISSN:1061-4036, Pages:984-+